Maureen D Moore1, Emily Postma2, Katherine D Gray1, Timothy M Ullmann1, James R Hurley3, Stanley Goldsmith3, Vivian R Sobel4, Aaron Schulman4, Theresa Scognamiglio5, Paul J Christos6, Erin Hassett1, Jessica Luick1, Dana Whitehall1, Rasa Zarnegar1, Thomas J Fahey7. 1. Department of Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, 10021, USA. 2. Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands. 3. Department of Nuclear Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. 4. Department of Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. 5. Department of Pathology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. 6. Department of Healthcare Policy and Research, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. 7. Department of Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, 10021, USA. tjfahey@med.cornell.edu.
Abstract
BACKGROUND: In 2006, a multidisciplinary thyroid conference (MDTC) was implemented to better plan management of thyroid cancer patients at our institution. This study assessed the clinical impact of a MDTC on radioactive iodine (RAI) treatment patterns. METHODS: A prospective database (2003-2014) collected patient and tumor characteristics, RAI doses, and tumor recurrences. Patients treated with total thyroidectomy for differentiated thyroid carcinoma ≥1 cm were stratified based on American Thyroid Association (ATA) risk classification. RAI regimens were compared before initiation of MDTC (2003-2005, n = 88), after establishment of MDTC (2007-2009, n = 95), and after the release of 2009 ATA guidelines (2011-2014, n = 181). RAI doses were defined as low (≤75 mCi), intermediate (76-150 mCi), and high (>150 mCi). RESULTS: There was a significant decrease in the number of patients who received high-dose RAI after implementation of MDTC compared to before initiation of MDTC in the intermediate and high-risk patient groups (p = 0.04 and p < 0.01) without an associated increase in tumor recurrence (11 vs. 7%, p = 0.74). On multivariable analysis, presentation of a patient at MDTC was a negative predictor for receiving high-dose RAI (p = 0.002). As might be expected, there was also a significant decrease in use of RAI after the 2009 ATA guidelines were issued compared to after implementation of MDTC (p < 0.01). CONCLUSION: In conjunction with implementation of a thyroid malignancy multidisciplinary conference, we observed significantly decreased postoperative dosing of RAI without increased tumor recurrence. The 2009 ATA guidelines were associated with a further decrease in RAI administration. Treatment for patients with thyroid carcinoma is optimized by a multidisciplinary approach.
BACKGROUND: In 2006, a multidisciplinary thyroid conference (MDTC) was implemented to better plan management of thyroid cancerpatients at our institution. This study assessed the clinical impact of a MDTC on radioactive iodine (RAI) treatment patterns. METHODS: A prospective database (2003-2014) collected patient and tumor characteristics, RAI doses, and tumor recurrences. Patients treated with total thyroidectomy for differentiated thyroid carcinoma ≥1 cm were stratified based on American Thyroid Association (ATA) risk classification. RAI regimens were compared before initiation of MDTC (2003-2005, n = 88), after establishment of MDTC (2007-2009, n = 95), and after the release of 2009 ATA guidelines (2011-2014, n = 181). RAI doses were defined as low (≤75 mCi), intermediate (76-150 mCi), and high (>150 mCi). RESULTS: There was a significant decrease in the number of patients who received high-dose RAI after implementation of MDTC compared to before initiation of MDTC in the intermediate and high-risk patient groups (p = 0.04 and p < 0.01) without an associated increase in tumor recurrence (11 vs. 7%, p = 0.74). On multivariable analysis, presentation of a patient at MDTC was a negative predictor for receiving high-dose RAI (p = 0.002). As might be expected, there was also a significant decrease in use of RAI after the 2009 ATA guidelines were issued compared to after implementation of MDTC (p < 0.01). CONCLUSION: In conjunction with implementation of a thyroid malignancy multidisciplinary conference, we observed significantly decreased postoperative dosing of RAI without increased tumor recurrence. The 2009 ATA guidelines were associated with a further decrease in RAI administration. Treatment for patients with thyroid carcinoma is optimized by a multidisciplinary approach.
Authors: Sally E Carty; Gerard M Doherty; William B Inabnet; Janice L Pasieka; Gregory W Randolph; Ashok R Shaha; David J Terris; Ralph P Tufano; R Michael Tuttle Journal: Thyroid Date: 2012-02-21 Impact factor: 6.568
Authors: Benjamin W Lamb; Katrina F Brown; Kamal Nagpal; Charles Vincent; James S A Green; Nick Sevdalis Journal: Ann Surg Oncol Date: 2011-03-26 Impact factor: 5.344
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Richard K Freeman; Jaclyn M Van Woerkom; Amy Vyverberg; Anthony J Ascioti Journal: Eur J Cardiothorac Surg Date: 2010-03-04 Impact factor: 4.191
Authors: Toni Beninato; Theresa Scognamiglio; David A Kleiman; Alessia Uccelli; Daniela Vaca; Thomas J Fahey; Rasa Zarnegar Journal: Surgery Date: 2013-12 Impact factor: 3.982
Authors: Timothy M Pawlik; Daniel Laheru; Ralph H Hruban; Joann Coleman; Christopher L Wolfgang; Kurt Campbell; Syed Ali; Elliot K Fishman; Richard D Schulick; Joseph M Herman Journal: Ann Surg Oncol Date: 2008-05-07 Impact factor: 5.344
Authors: N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez Journal: J Clin Endocrinol Metab Date: 1992-09 Impact factor: 5.958
Authors: Tayana Soukup; Konstantinos V Petrides; Benjamin W Lamb; Somita Sarkar; Sonal Arora; Sujay Shah; Ara Darzi; James S A Green; Nick Sevdalis Journal: Medicine (Baltimore) Date: 2016-06 Impact factor: 1.889